With an impressive background as an MD, and additional degrees in genetics, mathematics, and computational biology, Dr. Quin’s expertise in systems genomics is unparalleled. Holding doctorates from prestigious institutions like Oxford and Cambridge Universities, the South African Dr. notably founded his first liver drug genomics company 15 years ago.
By combining his medical expertise with computational biology, Dr. Quin’s company paved the way for groundbreaking discoveries in liver research and therapeutics. The insights gained from their work not only advanced the understanding of liver diseases but also laid the foundation for more effective, personalized, targeted treatments and improved patient outcomes. This contributions have undoubtedly impacted the medical community’s approach to liver disease management and brought hope to patients seeking better therapeutic options.
At the moment, Dr. Quin Wills is the co-founder and CSO of Ochre Bio, a revolutionary company that focuses on deep-phenotyping and tissue genomics, aiming to unravel the mysteries of liver metabolism and its connection to liver diseases, which are currently a major concern in Western society. Moreover, they are exploring the fascinating realm of liver transplants.
Our brilliant speaker is particularly socially aware, especially in advocating for inclusivity and equitable healthcare for all individuals, namely LGBTQ+ communities, who face unique health challenges and disparities which can be exacerbated by the lack of representation and understanding within the biopharmaceutical industry.